Phase I study of 5-FU + Oxaliplatin + Irinotecan + Levofolinate + Panitumumab as the first-line therapy in patients with KRAS or RAS wild-type metastatic colorectal cancer

Trial Profile

Phase I study of 5-FU + Oxaliplatin + Irinotecan + Levofolinate + Panitumumab as the first-line therapy in patients with KRAS or RAS wild-type metastatic colorectal cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Fluorouracil (Primary) ; Irinotecan (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms JACCRO CC-14
  • Most Recent Events

    • 15 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 05 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top